Physician profile
Michael Tomeo
NPI 1326046830
$10,191.78
in general payments reported to CMS, 2019-2025
29 companies · $398 in 2025
The $398 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,598 · 2020: $260 · 2021: $1,884 · 2022: $2,042 · 2023: $2,209 · 2024: $1,799 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,051 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.71 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $356.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,018.31 | 2019-2025 | Tremfya, Remicade, Simponi |
| Regeneron Healthcare Solutions, INC. | $913.76 | 2019-2024 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $902.10 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $874.23 | 2019-2024 | Ilumya, Absorica Ld, Winlevi |
| Abbvie INC. | $857.11 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $706.83 | 2021-2023 | |
| Lilly USA, LLC | $607.28 | 2019-2024 | Olumiant, Ebglyss, Taltz |
| Cepheid | $601.00 | 2021-2023 | |
| Amgen INC. | $587.84 | 2021-2024 | Otezla |
| Dermavant Sciences, INC. | $408.60 | 2023-2024 | Vtama |
| Pfizer INC. | $293.61 | 2019-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $254.19 | 2021-2024 | Valchlor |
| Leo Pharma INC. | $230.00 | 2019-2023 | Adbry |
| Ucb, INC. | $152.12 | 2021-2024 | Bimzelx, Cimzia |
| Organon LLC | $126.20 | 2025 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $119.70 | 2019-2024 | Sotyktu |
| Incyte Corporation | $116.38 | 2022-2023 | Opzelura |
| Epi Health, LLC | $81.73 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.22 | 2020-2023 | Jublia |
| Prugen, INC. Pharmaceuticals | $49.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.28 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.30 | 2023 | Spevigo |
| Encore Dermatology INC. | $37.35 | 2019 | |
| Galderma Laboratories, L.P. | $27.61 | 2019-2021 | |
| Dermira, INC. | $19.69 | 2020 | |
| Merck Sharp & Dohme LLC | $19.02 | 2023 | Keytruda |
| Vyne Pharmaceuticals INC. | $18.47 | 2020 | |
| Mission Pharmacal Company | $14.13 | 2021 | |
| Promius Pharma LLC | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tomeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.